- Current report filing (8-K)
05 Novembre 2008 - 10:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
November 5,
2008
ALLOS
THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No.)
|
|
|
|
|
|
11080
CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(303) 426-6262
Not applicable
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Section 2
|
|
Financial Information
|
|
|
|
Item 2.02
|
|
Results of Operations and Financial
Condition.
|
On November 5, 2008, Allos Therapeutics, Inc.,
a Delaware corporation (the Company), issued a press release relating to the
Companys financial results for the third quarter of fiscal year 2008.
The press release is attached hereto as Exhibit 99.1, which is furnished
under Item 2.02 of this report and shall not be deemed to be filed for
purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange
Act) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933
or the Exchange Act, regardless of any general incorporation language in such
filing.
Section 9
|
|
Financial Statements and Exhibits
|
|
|
|
Item 9.01
|
|
Financial Statements and Exhibits.
|
|
|
|
(d)
|
|
Exhibits.
|
|
|
|
99.1
|
|
Press Release,
dated November 5, 2008, entitled Allos Therapeutics Reports 2008 Third Quarter Results.
|
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Dated: November 5, 2008
|
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Marc H. Graboyes
|
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice President,
General Counsel and Secretary
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated
November 5, 2008, entitled Allos
Therapeutics Reports 2008 Third Quarter Results.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur